Sorin implants first new-generation CRT-D device
Sorin Group Cardiac Rhythm Management (CRM) has reported the first implant in a clinical trial of its Paradym 8770 sonR cardiac resynchronization therapy defibrillator (CRT-D).
The company said its system contains sonR, designed to adjust CRT delivery based on hemodynamic response as opposed to conventional CRT-D devices. Paradym sonR is the first device delivering continuous management of resynchronization therapy during patients’ everyday life, according to the Paris-based Sorin.
“Whereas conventional devices look at the heart as a ‘clock,’ new Paradym sonR looks at the heart as a ‘pump,’ measuring vibrations generated by heart contraction,” said Fred Hrkac, president of Sorin CRM business unit.
A multi-center clinical trial including 150 patients is currently being conducted across Europe. The company said its first sonR systems, the Paradym sonR CRT-D, including the sonR Fix atrial lead, were implanted by Angelo Auricchio, MD, from Cardiocentro Ticino in Lugano, Switzerland; Peter Paul Delnoy, MD from Isala Clinics in Zwolle, Netherlands; and Neil Sulke, MD from Eastbourne General Hospital in the East Sussex, England.
The company said its system contains sonR, designed to adjust CRT delivery based on hemodynamic response as opposed to conventional CRT-D devices. Paradym sonR is the first device delivering continuous management of resynchronization therapy during patients’ everyday life, according to the Paris-based Sorin.
“Whereas conventional devices look at the heart as a ‘clock,’ new Paradym sonR looks at the heart as a ‘pump,’ measuring vibrations generated by heart contraction,” said Fred Hrkac, president of Sorin CRM business unit.
A multi-center clinical trial including 150 patients is currently being conducted across Europe. The company said its first sonR systems, the Paradym sonR CRT-D, including the sonR Fix atrial lead, were implanted by Angelo Auricchio, MD, from Cardiocentro Ticino in Lugano, Switzerland; Peter Paul Delnoy, MD from Isala Clinics in Zwolle, Netherlands; and Neil Sulke, MD from Eastbourne General Hospital in the East Sussex, England.